{'fraction_non_alphanumeric': 0.023333333333333334, 'fraction_numerical': 0.0033333333333333335, 'mean_word_length': 7.013333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A case of haemodialysis‐associated pseudoporphyria successfully treated with oral N‐acetylcysteine

We report a 33‐year‐old woman with haemodialysis‐associated pseudoporphyria successfully responding to treatment with oral N‐acetylcysteine. We briefly review the current literature on bullous skin disorders in end‐stage renal disease, and compare and contrast the pathogenesis of pseudoporphyria and porphyria cutanea tarda in this context. We also discuss the antioxidant properties and clinical applications of N‐acetylcysteine, including the treatment of haemodialysis‐associated pseudoporphyria.